Biocure Technology (XCNQ:CURE) ROCE % : -5.39% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocure Technology's annualized ROCE % for the quarter that ended in Mar. 2024 was -5.39%.

Biocure Technology ROCE % Historical Data

The historical data trend for Biocure Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology ROCE % Chart

Biocure Technology Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-228.19

-190.98

-355.84

Biocure Technology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	4,615.52	-16.95	-750.84	-5.39

Biocure Technology ROCE % Calculation

Biocure Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.487	/	( ( (2.084 - 4.411)	+	(1.976 - 0.331) )	/ 2 )
	=	-1.487	/	( (-2.327	+	1.645)	/ 2 )
	=	-1.487	/	-0.341
	=	436.07 %

Biocure Technology's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-0.088	/	( ( (1.976 - 0.331)	+	(1.979 - 0.356) )	/ 2 )
	=	-0.088	/	( ( 1.645	+	1.623 )	/ 2 )
	=	-0.088	/	1.634
	=	-5.39 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Biocure Technology (XCNQ:CURE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocure Technology ROCE % Related Terms

Thank you for viewing the detailed overview of Biocure Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocure Technology (XCNQ:CURE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9

Website

https://www.biocuretech.com

Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.